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ple components, has been used in preclinical and clinical
studies to promote antitumor activity of T lymphocytes. To
define cellular mechanisms responsible for antitumor
effects of IRX-2, its ability to induce effector T cells (Teff)
was examined in a model simulating the tumor microenvi-
ronment. An in vitro model containing conventional
CD4
+CD25
− cells co-cultured with autologous immature
dendritic cells, irradiated tumor cells, and cytokines was
used to study differentiation and expansion of regulatory T
cells (Treg) and Teff in the presence and absence of IRX-2.
Phenotype, suppressor function, signaling, and cytokine
production were serially measured using flow cytometry,
Western blots, CFSE-based suppressor assays, and
Luminex-based analyses. The presence of IRX-2 in the
co-cultures promoted the induction and expansion of IFN-
+
+Tbet
+ Teff and significantly (p<0.01) decreased the
induction of inducible IL-10
+TGF-β
+ Treg. The responsible
mechanism involved IFN-+-driven T cell polarization
towards Teff and suppression of Treg differentiation. In an
in vitro model simulating the human tumor microenviron-
ment, IRX-2 promoted Teff expansion and antitumor
activity without inducing Treg. Thus, IRX-2 could be
therapies.
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Introduction
IRX-2 is a novel biologic containing low doses of
cytokines. It is produced by stimulating human peripheral
blood mononuclear cells (PBMC) with phytohaemaggluti-
nin (PHA). IRX-2 has been used in clinical trials for the
treatment of head and neck cancer (HNC) patients with
encouraging results and tolerable side effects [1]. The
delivery of IRX-2 to tumor-draining lymph nodes (LN) of
HNC patients reduced pain and dysphagia, decreased tumor
size and, in some patients, prolonged disease-free and
overall survival [1, 2]. IRX-2 also increased the number of
circulating naive and memory Tcells [3], enriched T cells in
tumor-draining LN [4], and promoted lymphocyte infiltra-
tions into the tumors [5]. In addition, in vitro studies
showed that IRX-2 enhanced dendritic cell (DC) maturation
[6] and protected cytotoxic T lymphocytes from tumor-
induced apoptosis [7]. Delivering of IRX-2 to tumor-
draining LN or into the tumor microenvironment was based
on the rationale that IRX-2 might alter local cell-to-cell
interactions, promote antitumor responses, and reduce
tumor-induced immunosuppression. Human tumors create
and maintain an environment enriched in immunosuppres-
sive cytokines, IL-10 and/or TGF-β, immunosuppressive
factors PGE2 or adenosine, and in regulatory T cells (Treg)
[8]. Thus, tumor-infiltrating immune cells are dysfunctional
and prone to apoptosis [8]. It has been suggested that
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contribute to the dysfunction of effector T cells [8].
While the available in vitro and in vivo data suggest that
IRX-2 enhances immune activation [5], the molecular
mechanisms responsible for IRX-2-mediated effects in the
tumor microenvironment are unknown. To evaluate IRX-2-
mediated effects on Teff and Treg, we used a previously
described in vitro model [9], in which human conventional
CD4
+CD25
− T cells are co-cultured with autologous
immature DC and with irradiated tumor cells in the
presence of low doses of recombinant human (rh) IL-2,
IL-10, and IL-15. This model mimics the tumor microen-
vironment and favors the generation of Treg from conven-
tional CD4
+CD25
− T cells [9]. The addition of IRX-2 to
this system allowed us to explore the cellular and molecular
mechanisms responsible for its ability to activate immune
cells in the tumor microenvironment.
Material and methods
IRX-2
To date, more than 40 patients have been treated with IRX-
2 in several Food and Drug Administration (FDA)-
approved clinical trials [2, 5]. IRX-2 is produced under
current good manufacturing practice (cGMP) conditions by
stimulation of human PBMCs with PHA for 24 h. PBMCs
are obtained from pretested leukocyte buffy coats pur-
chased from FDA-licensed blood banks. PHA and all
cellular elements are removed by centrifugation and
washing. DNA is removed by anion exchange chromatog-
raphy. The cell-free supernatant is nanofiltered for viral
clearance, filter sterilized, and formulated to defined
specifications for IL-2 and other cytokine levels. Stringent
QC testing including bioassays and ELISA for cytokine
levels assures the consistency of the IRX-2. As part of the
release criteria for clinical use of IRX-2, four cytokines (IL-
1β, IL-2, TNF-α, and IFN-+) are routinely measured in
ELISA assays standardized against World Health Organi-
zation (WHO) international standards. Testing for sterility,
DNA, mycoplasma, endotoxin, and viral nucleic acid for
cytomegalovirus and Epstein–Barr virus are also part of the
cGMP process. The IRX-2 lot used for our experiments
contains several cytokines at the concentrations listed in
Table 1.
Generation of immature DC and isolation
of CD4
+CD25
− cells
PBMCs were isolated by Ficoll-Hypaque (GE Healthcare,
Uppsala, Sweden) gradient centrifugation from buffy coats
purchased from the Central Blood Bank of Pittsburgh.
Monocytes were isolated by plastic adherence at 37°C for
2 h. Non-adherent cells were removed by washing.
Adherent cells were cultured in AIM V medium (Gibco
Invitrogen, Carlsbad, CA) containing 1,000 IU/mL IL-4
(Cellgenix, Freiburg, Germany) and 1,000 IU/mL GM-CSF
(Bayer, Seattle, WA). Immature monocyte-derived DC
(iDC) were harvested on day 6. CD4
+CD25
− T cells were
isolated from the remaining non-adherent cells by magnetic
bead separation using Treg isolation kits (Miltenyi, Auburn,
CA) asrecommendedbythe manufacturerandcryopreserved.
Cell culture
PCI-13, an HNC cell line, established and maintained in
our laboratory [10] was cultured in RPMI 1640 medium
(Lonza) supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (FBS), L-glutamine 2 mmol/l, 100 IU/mL
penicillin, and 100 μg/mL streptomycin in an atmosphere
of 5% CO2 in air at 37°C. K562, a human leukemic cell
line, was purchased from ATCC and cultured in RPMI 1640
supplemented with 10% heat-inactivated FBS, L-glutamine,
penicillin, and streptomycin. The cells were routinely tested
for Mycoplasma and endotoxin levels and were found to be
negative.
The co-culture model system
The in vitro model simulating the human tumor microen-
vironment contained 5×10
5 iDC co-cultured with 5×10
5
irradiated (3,000 rad) PCI-13 cells and autologous
CD4
+CD25
− T cells (5×10
6) in six-well plates [9]. Each
Table 1 Cytokines present in the IRX-2 lot 051308 used for the
described experiments
Cytokine Concentration (ng/mL)
IL-2 5.0
IL-1b 0.94
IFN-+ 2.2
TNF-α 1.7
IL-8 35.3
IL-6 1.2
GM-CSF 0.27
TGF-β Not detectable
a
The IRX-2 lot was supplied by IRX Therapeutics Inc. (Farmingdale,
NY). Cytokine levels were determined by ELISA and provided by
IRX Therapeutics Inc. The levels of the cytokines present in the IRX-
2 lot 051208 used in the described experiments were measured as
described in “Materials and methods” section. The conversion from
picogram to to International Unit was based on ELISA performed with
the WHO international standards (in International Unit)
aTGF-β was not detectable in IRX-2 lot 051208 by a cytokine array
performed by IRX Therapeutics Inc.
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were cultured in an atmosphere of 5% CO2 in air at 37°C
for 10 days. In addition, 2.5 mL aliquots of IRX-2 or X-
Vivo 10 medium (control) were added to each well as well
as rhIL-2 (10 IU/mL), IL-10 (20 IU/mL), and IL-15 (20 IU/
mL) (Peprotech, Rocky Hill, NJ). On days 3, 6, and 9, half
of the medium was removed and replaced with fresh
cytokine-containing medium mixed 1:1 with medium or
IRX-2. For cytokine assays, cells were stimulated for 16 h
with anti-CD3/CD28-coated beads (Miltenyi) at the bead:
cell ratio of 1:1 in complete AIM V medium without
exogenous cytokines or IRX-2. For intracellular cytokine
staining, Brefeldin A (2 μg/mL, Sigma-Aldrich, St. Louis,
MO) was added to the cells.
Flow cytometry staining and antibodies
The following anti-human flourochrome-conjugated anti-
bodies were purchased from Beckman Coulter: anti-CD4-
ECD, anti-CD3-PeCy5, anti-CD25-FITC, anti-CD25-PE,
and anti-CTLA4-PE. In addition, anti-IL-10-FITC was
purchased from R&D Systems. Anti-CD122-PE and anti-
CD132-PE were obtained from BD Pharmigen and anti-
TGF-β1 (clone TB21) from IQ products (Groningen,
Netherlands). Anti-FOXP3-FITC (clone PCH101), anti-IL-
17-PE, and anti-T-bet-PE were from eBioscience. A PE-
conjugated anti-phospho-Akt (Ser473) was purchased from
Cell Signaling as was an unconjugated mouse anti-Akt
antibody. A PE-conjugated donkey anti-mouse Fab was
purchased from eBioscience.
For staining, cells were harvested, washed, and incubat-
ed with human Fc-block (eBioscience, San Diego, CA)
according to the manufacturer’s instructions. Antibodies
were added, and staining was performed for 20 min on ice.
Cells were washed and fixed with phosphate-buffered
saline (PBS) containing paraformaldehyde 2% (w/v in
PBS) prior to analysis. For intracellular staining, cells were
permeabilized using a Fix/Perm Kit from eBioscience. For
FOXP3 and T-bet detection, a staining kit from eBioscience
was used. Incubations were performed on ice for 30 min,
a n dw a s h e dc e l l sw e r ea c q u i r e do nt h es a m ed a y .
Incubations with a labeled secondary antibody were
performed for 30 min on ice. For intracellular staining of
Akt and phospho-Akt, cells were fixed with 2% parafor-
maldehyde (w/v) in PBS and permeabilized with ice-cold
methanol. Incubations with primary antibodies were per-
formed for 1 h at room temperature.
Luminex
Cytokine levels in cell supernatants were measured using
the Luminex© technology according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA).
Western blots
Cells were washed, centrifuged at 4°C, and lysed in equal
volumes of ice-cold lysis buffer [50 mM Tris–HCl
(pH 7.5), 150 mM NaCl, 0.5% Nonidet P-40] and protease
inhibitor cocktail (Pierce Chemical Co., Rockford, IL,
USA). Homogenates were clarified by centrifugation.
Supernatants were boiled for 5 min in Laemmli sample
buffer (Bio-Rad, Hercules, CA). Equivalent protein quan-
tities, as determined by Lowry, were loaded on each gel.
Proteins were separated by SDS-PAGE electrophoresis and
electrotransferred to polyvinylidene difluoride membranes.
The membranes were developed as previously described
[7]. Primary antibodies against human STAT molecules
were purchased from Cell Signaling, and a horseradish
peroxidase-conjugated secondary antibody from Pierce
Chemical Company.
CFSE-based suppression assay
Suppression of proliferation of CD4
+CD25
− T cells was
performed as previously described [11]. Briefly,
CD4
+CD25
− responder cells (RC) labeled with 1.5 μM
carboxyfluorescein succinimidyl ester (CFSE, Invitrogen,
Carlsbad, CA) were cultured in complete AIM V medium
in the presence of 150 IU/mL rhIL-2 and 1 μg/mL anti-
CD28 mAb (Miltanyi) in wells of 96-well plates (10
5/well)
coated with anti-CD3 mAb (1 μg/mL, eBioscience). T cells
harvested from the IVA co-cultures were added to the RC at
different ratios and cultures were incubated in 5% CO2 in
air at 37°C. Flow cytometry analyses were performed on
day 4, the ModFit LT software provided by Verity Software
House Inc. was used for data processing (Topsham, ME).
Statistical analysis
Data were analyzed using paired Student’s t tests. The p
values <0.05 were considered significant.
Results
IRX-2 promotes expansion of Teff
CD4
+CD25
− T cells in the co-cultured in our in vitro system
proliferate and differentiate into adaptive Treg (Tr1) with a
distinctive phenotype [9]. The addition of IRX-2 to co-
cultures had no impact on cell proliferation or their viability
(Fig. 1a). T cells placed in culture (day 0) were
CD3
+CD4
+CD25
−CD122
−CD132
−CD152
−FOXP3
−.O n
day 0, co-cultures contained few (0.4±0.1×10
6)I F N - +
+
Teff and no Tr1 (Fig. 1b). The cells become CD25
+,
CD122
+, CD132
+,C D 1 5 2
+, and FOXP3
+ (Fig. 2a, b), and
J Mol Med (2012) 90:139–147 141the frequency of T cells expressing IL-10, TGF-β1, and
IFN-+ is significantly increased by day 10 (Fig. 2c, d). In
the course of the co-culture, the starting population
gradually acquires the Tr1 phenotype in the absence of
IRX-2 (Fig. 1b, gray lines), and the number of Teff
i n c r e a s e so n l ys l i g h t l yt o1 . 1 ± 0 . 2 × 1 0
6 on day 10. In
contrast, upon IRX-2 addition, the number of outgrowing
Tr1 decreases while that of Teff increases (Fig. 1b, black
lines). The addition of IRX-2 to the co-culture resulted in a
dose-dependent change in the phenotype of proliferating T
cells and in a significant decrease in the proportion of T
cells with the Tr1 phenotype (Fig. 1b). The maximal effects
were observed with IRX-2 used at the 1:1 dilution. As
s h o w ni nF i g .2a, b, the mean percentages of CD3
+CD4
+
cells expressing CD25 (53% vs. 24%), CD122 (55% vs.
20%), CD132 (57% vs. 25%), CD152 (57% vs. 29%), and
FOXP3 [49% vs. 28%, mean fluorescence intensity (MFI)
12.6 vs. 6.3] were lower (p<0.01 for all) when the cells
were cultured in the presence of IRX-2. In addition, as
s h o w ni nF i g .2c, d, in the presence of IRX-2, the
percentage of IL-10
+ and TGF-β1
+ T cells decreased, while
that of IFN-+
+ cells increased. In the absence of IRX-2, the
mean percentage of IL-10
+ cells within the CD3
+CD4
+ T
cells was 57%, and 62% were TGF-β1
+, while only 10%
were IFN-+
+. In the presence of IRX-2, only 22% cells
were IL-10
+ (p<0.01) and 34% were TGF-β1
+ (p<0.01),
while Tcells expressing INF-+ i n c r e a s e dt o3 4 %( p<0.01).
IL-17 was not detectable in any of these co-cultures
(Fig. 2d).
T cells cultured in the presence of IRX-2 predominantly
produce Teff cytokines
The cytokine profile of the Tcells generated in the presence
or absence of IRX-2 was analyzed in Luminex-based assays
using culture supernatants. Luminex assays of IRX-2 mixed
1:1 with complete AIM V medium showed low levels of
IL-4 (16 pg/mL), IL-10 (79 pg/mL), and IL-17 (25 pg/mL).
As shown in Fig. 3, restimulation of Tcells generated in the
presence of IRX-2 with anti-CD3/CD28 Ab-coated beads
for 24 h resulted in significantly higher levels of IFN-+
(3,129 vs. 975 pg/mL/10
6, p<0.01) than restimulation of
those cells generated in control cultures (medium alone). In
contrast, T cells cultured in the absence of IRX-2 produced
significantly higher levels of IL-10 (1,680 vs. 740.5 pg/mL/
10
6, p<0.01) and TGF-β1( 8 8 1v s .2 9 0p g / m L / 1 0
6, p<0.01)
(Fig. 3). These data show that the addition of IRX-2 favored
the induction of IFN-+-producing Teff, while in the absence
of IRX-2, mainly IL-10- and TGF-β1-producing Tr1 were
induced in the co-cultures.
Fig. 1 IRX-2 effects on Tr1 and
Teff cells in the co-culture mod-
el. a Proliferation and
viability of cells cultured in the
presence or absence of IRX-2.
Mean number of cells±SD and
mean viability from four
independent experiments are
shown. b The outgrowth of Teff
and Tr1 in 10-day co-cultures:
Cells were cultured in the
presence (black lines)o r
absence of IRX-2 (gray lines).
Cells were sampled, counted,
and phenotyped by flow
cytometry at the indicated time
points. IRX-2 decreased the
number of outgrowing Tr1
(p<0.01) and increased the
number of Teff as compared to
co-cultures in the absence of
IRX-2. The data are mean
numbers of cells±SD
established in three independent
experiments
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suppressor function
Next, in CFSE-based proliferation assays, we measured
suppression of the proliferation of autologous RC by Tcells
generated in the presence or absence of IRX-2. Figure 4
shows that T cells induced in the absence of IRX-2 mediate
significantly stronger suppression of RC proliferation than
T cells generated in the presence of IRX-2 (67% vs. 35%
suppression, p<0.05). Consistent with the phenotype and
the cytokine profile of T cells generated in the presence of
IRX-2, their suppressor function was significantly reduced
relative to that of T cells cultured without IRX-2.
IRX-2 upregulates T-bet and pAkt but downregulates
pSTAT5 in T cells
To identify molecular pathways responsible for the effects
mediated by IRX-2, induction of T-bet, the transcription
Fig. 2 Phenotype of
CD4
+CD25
− T cells after
10-day co-culture ±IRX-2.
a Representative histograms of T
cells cultured for 10 days in the
presence or absence of IRX-2.
b Cells cultured in the presence
of IRX-2 (black bars) expressed
significantly lower levels of the
Tr1-associated markers: CD25,
CD122, CD132, CD152,
and FOXP3 (*p<0.01).
c Representative histograms for
intracellular cytokine staining on
day 10 of co-culture. d The
percentages of IL-10
+ and
TGF-β
+ cells were lower when T
cells were cultured in the
presence of IRX-2, while the
percentages of IFN-+
+ were
higher relative to those
cultured in the absence of IRX-2
(*p<0.01). The cultured cells
were phenotyped on day 10.
The data obtained from five
independent experiments are
shown as mean percentages±SD
of positive cells in the
CD3
+CD4
+ gate
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[12], was examined in T cells generated ±IRX-2 in the co-
culture system. As shown in Fig. 5a, b, intracellular
staining revealed significantly higher levels of T-bet in T
cells cultured in the presence of IRX-2 as compared to
those cultured in media alone (mean MFI 0.93 vs. 2.7, p<
0.01). Next, we observed that IRX-2 induced greater Akt
phosphorylation in T cells as compared to controls (mean
MFI 9.4 vs. 13, p<0.01) (Fig. 5c, d), while total Akt levels
were not significantly different (mean MFI 6.8 vs. 7, p>
0.05). Western Blot analyses for STAT signaling in T cells
demonstrated lower levels of phosphorylated STAT5
(pSTAT5) in T cells cultured in the presence of IRX-2 than
those cultured in its absence, while the total STAT5 levels
were unchanged (Fig. 5f).
IRX-2 treatment does not increase Treg numbers
in the patients’ peripheral blood
Since IRX-2 contains IL-2, we expected it to increase the
frequency of circulating Treg when given to patients with
cancer as previously reported for rhIL-2 or antitumor
vaccines [13]. We were able to study peripheral blood
specimens obtained from the HNC patients treated with the
IRX-2 as part of the recently completed phase II trial with
IRX-2 [Berinstein et al., submitted]. Twenty-five patients
with HNC received neoadjuvant therapy with IRX-2 prior
to surgery. IRX-2 was delivered perilymphatically each day
for 10 days starting on day 4 and following an infusion of
low dose cyclophosphamide on day 1 and daily oral
indomethacin and zinc in multivitamins [Berinstein et al.,
submitted]. Peripheral blood specimens were obtained from
each patient pre- (day 1) and post- (day 21) IRX-2 therapy,
and the frequency as well the absolute numbers of
CD3
+CD4
+CD25
hi T cells were determined. Consistent
with our previous reports [14], the Treg frequency was
increased in HNC patients prior to therapy (12±3% mean±
SEM in the CD3
+CD4
+ gate) as compared to normal
controls (2±1.5%). The percentage of Treg remained
unchanged after IRX-2 therapy (pre 6.7±0.6% vs. post
7.5±0.8%), and so did their absolute number (pre, 53±6/ μL
vs. post, 52±7/μL, mean±SEM). The ratio of CD8
+ Teff
cells to Treg remained unchanged at 6.6 in the patients’
peripheral blood. These data indicated that unlike rhIL-2,
IRX-2 did not increase the frequency of Treg in the
patients’ peripheral blood.
Discussion
This study evaluated the effects of a novel immunothera-
peutic, IRX-2, on T cell polarization in an in vitro model
simulating the human tumor microenvironment. In this
model, IRX-2 prevented the induction of inducible Treg
(Tr1) and favored the differentiation of Teff.
We previously reported the increased frequency of Treg
in the peripheral blood and within tumor-infiltrating
lymphocytes (TIL) of HNC patients [14, 15]. The prognos-
Fig. 4 Suppression mediated by T cells generated in co-cultures
±IRX-2. Cells harvested from co-cultures on day 10 were added
to CFSE-labeled autologous responder cells at different ratios as
described in the “Materials and methods” section. A cell–dose-
dependent suppression of RC proliferation by T cells generated
±IRX-2 is presented. T cells cultured in the presence of IRX-2
showed lower suppression of proliferation (*p<0.05). The data are
mean percentages of suppression±SD from four independent
experiments
Fig. 3 Profile of cytokines secreted by cultured T cells ±IRX-2. T
cells were harvested from co-cultures on day 9 and were stimulated
with anti-CD3/CD28 Ab-coated beads for 24 h. The supernatants
were analyzed for cytokine levels. In the presence of IRX-2
(black bars), T cells secreted significantly more IFN-+ (*p<0.01)
than those cultured in its absence (open bars), while IL-4 levels were
not different (p>0.05). In addition, supernatants from cells cultured
in the presence of IRX-2 produced lower levels of IL-10 and TGF-β
(*p<0.01). The data are mean concentrations of cytokines±SD from
five independent experiments
144 J Mol Med (2012) 90:139–147tic impact of Treg accumulations in HNC is unknown [14,
16], although in other human solid tumors, the increased
Treg frequency among TIL has been variously linked to
better or worse prognosis [17–20]. In HNC, infiltrations of
primary tumors with activated CD4
+ T cells have been
reported to correlate with improved overall survival [21].
This suggests that therapies increasing Teff within TIL
could be beneficial in HNC and that alterations in the tumor
microenvironment could benefit antitumor immunity.
CD4
+ T cells are characterized by plasticity [12]. CD4
+ T
cells cultured in the absence of IRX-2 acquired the Treg
phenotype and immunosuppressive cytokine profile. In
contrast, in the presence of IRX-2 CD4
+ Tc e l l sh a da
phenotype characteristic of Teff and produced IFN-+ rather
than TGF-β1 and IL-10. Thus, IRX-2 favored CD4
+ Tc e l l
differentiation into Teff rather than Tr1. Functionally, T cells
cultured in the absence of IRX-2 were strongly suppressive,
while T cells polarized by IRX-2 mediated significantly
reduced suppression. IRX-2 did not completely prevent
the induction of Tr1 but rather shifted the ratio of Treg/
Teff towards Teff. Specifically, the average TGF-β1/IFN-
+ ratio was 6:1 without IRX-2 vs. 1:1.2 with IRX-2. IRX-2
did not affect T cell proliferation or their viability,
suggesting that it does not eliminate any T cells but rather
expands Teff.
We and others have reported that inhibition of the
mammalian target of rapamycin (mTOR) pathway with
rapamycin promotes Treg expansion [22, 23], while
activation of the Akt–mTor pathway antagonizes the
induction of FOXP3
+ cells [24]. A significant increase in
the level of pAkt is observed when T cells are cultured in
the presence of IRX-2. In human Treg, the restoration of
Akt activity reduces Treg-mediated suppression [25]. Thus,
enhanced Akt phosphorylation by IRX-2, leading to
activation of the Akt–mTOR pathway, is a likely mecha-
nism responsible for shifting the balance toward Teff
Fig. 5 Effects of IRX-2 on
T cell signaling. T cells were
cultured for 10 days, harvested,
and tested for the expression of
intracellular T-bet, Akt, and
pAkt by flow cytometry. a, c,
and e show representative
histograms gated on CD3
+CD4
+
cells cultured in the presence
(closed line) or absence
(open line) of IRX-2. Isotype
controls are shown in gray. Cells
cultured in the presence of
IRX-2 express higher levels of
T-bet (a, b,* p<0.01) and pAkt
(c, d,* p<0.01) while expression
of total Akt did not differ
between IRX-2 and control
(e, p>0.05). The data in bar
plots are mean MFI±SD of cells
gated on CD3
+CD4
+ from four
independent experiments
harvested on day 10. f A
representative Western blot of
three experiments performed
shows data obtained with lysates
of cells prepared on day 10.
Total STAT5 expression
(middle row) was similar after
a co-culture ±IRX-2. T cells
cultured +IRX-2 contained a
lower level of pSTAT5 level
(upper row). K562 cell line
constitutively expressing
pSTAT5 served as a positive
control. Freshly isolated PBMC
also expressed pSTAT5
J Mol Med (2012) 90:139–147 145differentiation and reduction of FOXP3 expression in the
co-culture system. Also, IRX-2-mediated Akt activation
was shown to protect CD4
+ and CD8
+ T cells from tumor-
induced apoptosis [7].
The differentiation of Teff is known to be influenced by
IFN-+, which stabilizes T-bet expression [26]. Also, IFN-+
facilitates the conversion of CD4
+CD25
− cells into func-
tional CD4
+CD25
+FOXP3
+ Treg in humans and mice [27].
Thus, its presence in the co-culture could influence
differentiation of Teff as well as Treg. IRX-2 contains
considerable levels of IFN-+ (e.g., 2.2 ng/mL). Thus, T-bet
expression and thereby Teff induction in the presence of
IRX-2 might be driven by IFN-+. IRX-2 contains multiple
naturally occurring cytokines, and it is possible that more
than one cytokine contributes to a shift in the phenotype
and function of cultured T cells.
IL-2 is known to promote T cell-mediated antitumor
immunity in patients with cancer [28]. It is also required
for Treg expansion and activity [29]. In renal cell
carcinoma and melanoma patients treated with a high
dose of rhIL-2, significant increases of Treg in the
peripheral circulation were reported [13]. In contrast, we
did not observe increases in numbers or frequency of Treg
in HNC patients treated with neoadjuvant IRX-2 in the
phase II trial, although IRX-2 contained ∼6n g( i . e . ,
125 IU/mL) of IL-2. Furthermore, an increase in lympho-
cytic infiltrates in tumor samples obtained from HNC
patients before and after the neoadjuvant IRX-2 treatment
was associated with improved survival [Berinstein et al.,
submitted].
In vivo, Treg survival critically depends on the activation
of the IL-2 receptor and STAT5 signaling [29, 30]. CD25-
or CD122-deficient mice lack Treg and STAT5-deficient
mice show dramatically decreased Treg frequency because
Foxp3 expression is directly controlled by activation of
STAT5 [31]. It has also been suggested that the inhibition of
Akt/mTOR pathway in the presence of IL-2 leads to
persistent activation of STAT5 and Treg expansion [23].
Limiting STAT5 phosphorylation decreases Treg suppressor
function [32]. IL-2-induced STAT5 activation provides an
explanation for the increased Treg frequency in cancer
patients treated with rhIL-2 [13]. The observed lower pSTAT5
levels in T cells cultured with IRX-2 suggests that IRX-2
favors Teff differentiation rather than Treg expansion. Further,
IRX-2 did not increase the Treg frequency or numbers in the
peripheral circulation of patients treated with IRX-2 in the
recent phase II clinical trial [Berinstein et al., submitted].
In tumor-bearing hosts, the induction of robust antitumor
responses is desirable. The ability to manipulate the tumor
microenvironment so that it favors the differentiation of Teff
cells rather than Treg represents a promising immunother-
apeutic strategy. While many current therapies aim at
eliminating or silencing Treg, the alternative approach of
protecting and augmenting functions of Teff is equally
important. In this study, using an in vitro model simulating
the tumor microenvironment, we show that IRX-2 promotes
Teff differentiation and helper functions without inducing
Treg. In the clinic, IRX-2 administered to the vicinity of
tumor-draining LN in HNC patients exerted multiple effects
on immune cells and prolonged survival [Berinstein et al.,
submitted]. Thus, IRX-2 might be a promising component
of future cancer therapies.
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